The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.
Kiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.
Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.
Okie, let’s look at the market. As I am very busy recently, my post is a lot slower. But, I am still monitoring the market closely. Today, the posts will be long, and the contents are as below: i) Current market-$SPDR S&P 500 ETF(SPY.US)$ ii) Oil price iii) My trade based on stage analysis i) To be honest, after the last month CPI showed that the inflation is still not under controlled, the big sell off volume ha...
キニクサ・ファーマシューティカルズに関するコメント
Upcoming Ph 2 readouts in Q1 2024…
$リジェネックスバイオ(RGNX.US)$ Phase 2
$リープ・セラピューティクス(LPTX.US)$ Phase 2
$4Dモレキュラー・セラピューティクス(FDMT.US)$ Phase 2
$アドベラム・バイオテクノロジーズ(ADVM.US)$ Phase 2
$デナリ・セラピューティクス(DNLI.US)$ Phase 2
$アイポイント・ファーマシューティカルズ(EYPT.US)$ Phase 2
$ゼンコー(XNCR.US)$ Phase 2
$ハーモニー・バイオサイエンシーズ(HRMY.US)$ Phase 2
$アルナイラム・ファーマシューティカルズ(ALNY.US)$ Phase 2
$ディスク・メディシン(IRON.US)$ Phase 2
$アテア・ファーマシューティカルズ(AVIR.US)$ Phase 2
$アラコス(ALLK.US)$ Phase 2...
Market analysis- 09Oct2022
i) Current market- $SPDR S&P 500 ETF(SPY.US)$
ii) Oil price
iii) My trade based on stage analysis
i) To be honest, after the last month CPI showed that the inflation is still not under controlled, the big sell off volume ha...
まだコメントはありません